Figure 2.
MZ B cells play a role in anti-HOD alloantibody formation. (A-B) Gating strategy (A) and quantification (B) of the percentage of B220+CD23−CD21hi MZ B cells in splenocytes obtained from MZ-KO and CD19+/+ × Notch2flx/flx (MZ-KO Ctrl) mice. (C-D) Representative line graph (C) and quantification (D) of anti-HOD IgM alloantibody formation in MZ B-cell–KO mice (blue) compared with MZ B-cell–KO littermate control mice (red) following HOD RBC transfusion. (E-F) Representative line graph (E) and quantification (F) of anti-HOD IgG alloantibody formation in MZ B-cell–KO mice (blue) compared with MZ B-cell–KO littermate control mice (red) following HOD RBC transfusion.

MZ B cells play a role in anti-HOD alloantibody formation. (A-B) Gating strategy (A) and quantification (B) of the percentage of B220+CD23CD21hi MZ B cells in splenocytes obtained from MZ-KO and CD19+/+ × Notch2flx/flx (MZ-KO Ctrl) mice. (C-D) Representative line graph (C) and quantification (D) of anti-HOD IgM alloantibody formation in MZ B-cell–KO mice (blue) compared with MZ B-cell–KO littermate control mice (red) following HOD RBC transfusion. (E-F) Representative line graph (E) and quantification (F) of anti-HOD IgG alloantibody formation in MZ B-cell–KO mice (blue) compared with MZ B-cell–KO littermate control mice (red) following HOD RBC transfusion.

Close Modal

or Create an Account

Close Modal
Close Modal